A Study of HW243040 in Healthy Participants
ConditionHealthy
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorHubei Bio-Pharmaceutical Industrial Technological Institute Inc.
About this trial
This is a randomised, double-blind, placebo-controlled clinical trial intended to evaluate the safety, tolerability and pharmacokinetic profiles of HW243040 following single and multiple administrations in healthy study participants.
Eligibility criteria
Qualifiers
Informed consent must be obtained/signed prior to trial participation.
Aged between 18 and 55 years old, both healthy males and females are eligible.
Female participates must have a body weight of ≥ 45 kg and male participates ≥ 50 kg, with a body mass index (BMI) ranging from 19 to 26 kg/m².
Disqualifiers
History or presence of any clinically severe disorders of urinary, cardiovascular, endocrine, nervous, gastrointestinal, respiratory, hematologic, immune systems, psychiatric illnesses or metabolic abnormalities; or other conditions judged by the Investigator to confound trial outcomes, e.g., intestinal diseases (irritable bowel syndrome), urinary tract infections.
History of malignant tumors (except for cancer with confirmed cure or remission for ≥5 years, radically resected basal or squamous cell skin cancer, carcinoma in situ of the cervix, and resected colonic polyps).
Any conditions or diseases that, in the Investigator's judgment, may affect the absorption, metabolism and/or excretion of the investigational product.
History of drug abuse or dependence.
Trial design
Treatments tested in this trial
- HW243040
- Placebo
Treatment groups
98 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov